Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Albiglutide

MARKETED

GLP-1 receptor agonist

2
graded findings
2
effect domains
Evidence spread
High evidence 1Moderate evidence 1Low evidence 0Very low evidence 0

Albiglutide is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Albiglutide MARKETED
Cardiovascular outcomes Decrease
High evidence

In T2D with established CVD, albiglutide reduced MACE versus placebo, a superiority result driven notably by reduced myocardial infarction.

Hernandez AF et al., Lancet, 2018 Source
PopulationHARMONY Outcomes: N=9463; T2D with established CVD; double-blind placebo-controlled RCT; median 1.6 years (short).
Fundingindustry - GlaxoSmithKline
Scope limitsADDED. MI-driven superiority, contrasting the stroke-driven SUSTAIN-6/REWIND; recorded as observation. Albiglutide later withdrawn from market for commercial (not safety) reasons.
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Albiglutide MARKETED
Glycaemic control Decrease
Moderate evidence

Once-weekly albiglutide (30/50 mg) monotherapy reduced HbA1c by approx 0.8% vs placebo (HARMONY 2); in HARMONY Outcomes it reduced MACE by ~22% vs placebo. Weight loss...

Hernandez AF et al., Lancet 2018 (HARMONY Outcomes); Reusch J et al., Diabetes Obes Metab... Source
Full findingOnce-weekly albiglutide (30/50 mg) monotherapy reduced HbA1c by approx 0.8% vs placebo (HARMONY 2); in HARMONY Outcomes it reduced MACE by ~22% vs placebo. Weight loss was modest and lower than competing GLP-1 RAs.
PopulationHARMONY 2: T2D inadequately controlled with diet/exercise, 52 weeks, placebo-controlled. HARMONY Outcomes: 9463 T2D with CV disease, median 1.6 years, vs placebo
Fundingindustry - GlaxoSmithKline
Scope limitsMechanism: two tandem GLP-1(7-36) copies fused to recombinant human albumin (once-weekly). Marketed Tanzeum (US)/Eperzan (EU); GSK withdrew worldwide July 2018 for commercial reasons (lower efficacy/weight effect) despite positive CV outcomes. Historical/withdrawn landscape row.
Comparatorsplacebo